Sequent Scientific Limited Receives WHO Prequalification Approval for Albendazole API

On August 19, 2024, Sequent Scientific Limited, a leading Indian pharmaceutical company, announced that it had received prequalification (PQ) approval from the World Health Organization (WHO) for its Albendazole Active Pharmaceutical Ingredient (API).

This approval was achieved in partnership with Mepro Pharmaceuticals Private Limited, which developed and commercialised the Albendazole Chewable formulation using Sequent’s API. Notably, Mepro’s Chewable formulation is the first of its kind to receive global approval from WHO PQ.

Albendazole is an essential medication used to treat various parasitic infections, such as tapeworm, roundworm, and hookworm, which impact millions of people, especially in low and middle-income countries. The WHO prequalification underscores Sequent Scientific Limited’s dedication to meeting high international standards for producing Albendazole API, ensuring its safety, quality, and effectiveness.

“The WHO prequalification approval validates our manufacturing capabilities and reinforces our dedication to providing high-quality, affordable medicines to those in need worldwide. By leveraging our extensive distribution network and strategic partnerships, the company is poised to make a meaningful impact on health outcomes on a global scale,” said Rajaram Narayanan, MD and CEO of Sequent Scientific Limited.

Financial Highlights

Sequent Scientific Limited’s net sales for March 2024 were ₹361.20 crore, a slight decrease of 1.49% compared to ₹366.67 crore in March 2023. The quarterly net loss improved significantly, standing at ₹0.91 crore in March 2024, a 99.03% improvement from a loss of ₹93.57 crore in March 2023. The company’s EBITDA saw a substantial increase, reaching ₹36.26 crore in March 2024, up by 2324.54% from ₹1.63 crore in March 2023.

About Sequent Scientific Limited

Sequent Scientific Limited is India’s top animal health company, reporting a consolidated revenue of ₹13.69 billion for FY24. Operating through its subsidiaries, the company is active in over 90 countries and has 7 manufacturing facilities, providing services to customers across the globe.

About Mepro

Mepro Pharmaceuticals is a privately owned company with more than 40 years of experience providing quality healthcare to highly regulated markets like the UK, EU, Canada, and Australia. Based in Mumbai, India, the company develops and manufactures specialised and technically complex pharmaceutical products at its four manufacturing facilities.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.